ALX Oncology Holdings Inc (ALXO)
8.44
-0.10
(-1.17%)
USD |
NASDAQ |
Jun 13, 16:00
8.44
0.00 (0.00%)
After-Hours: 17:32
ALX Oncology Holdings Enterprise Value: 297.20M for June 12, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| June 12, 2024 | 297.20M |
| June 11, 2024 | 298.24M |
| June 10, 2024 | 303.97M |
| June 07, 2024 | 321.69M |
| June 06, 2024 | 335.75M |
| June 05, 2024 | 310.75M |
| June 04, 2024 | 288.34M |
| June 03, 2024 | 319.08M |
| May 31, 2024 | 406.09M |
| May 30, 2024 | 407.13M |
| May 29, 2024 | 435.27M |
| May 28, 2024 | 506.64M |
| May 24, 2024 | 538.42M |
| May 23, 2024 | 617.62M |
| May 22, 2024 | 633.77M |
| May 21, 2024 | 561.87M |
| May 20, 2024 | 570.73M |
| May 17, 2024 | 592.61M |
| May 16, 2024 | 616.05M |
| May 15, 2024 | 634.81M |
| May 14, 2024 | 642.62M |
| May 13, 2024 | 665.55M |
| May 10, 2024 | 696.81M |
| May 09, 2024 | 735.36M |
| May 08, 2024 | 717.65M |
| Date | Value |
|---|---|
| May 07, 2024 | 767.14M |
| May 06, 2024 | 674.41M |
| May 03, 2024 | 652.52M |
| May 02, 2024 | 718.17M |
| May 01, 2024 | 707.72M |
| April 30, 2024 | 711.76M |
| April 29, 2024 | 707.21M |
| April 26, 2024 | 703.68M |
| April 25, 2024 | 704.18M |
| April 24, 2024 | 671.36M |
| April 23, 2024 | 635.00M |
| April 22, 2024 | 570.86M |
| April 19, 2024 | 640.05M |
| April 18, 2024 | 647.12M |
| April 17, 2024 | 664.29M |
| April 16, 2024 | 583.99M |
| April 15, 2024 | 503.20M |
| April 12, 2024 | 507.38M |
| April 11, 2024 | 524.97M |
| April 10, 2024 | 458.11M |
| April 09, 2024 | 472.69M |
| April 08, 2024 | 462.63M |
| April 05, 2024 | 467.16M |
| April 04, 2024 | 417.38M |
| April 03, 2024 | 395.26M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-76.99M
Minimum
Jun 16 2022
3.912B
Maximum
Dec 10 2020
880.56M
Average
407.13M
Median
May 30 2024
Enterprise Value Benchmarks
| Bristol-Myers Squibb Co | 132.03B |
| Annovis Bio Inc | 64.79M |
| Verastem Inc | 42.23M |
| AbbVie Inc | 349.26B |
| Nurix Therapeutics Inc | 763.62M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -35.58M |
| Total Expenses (Quarterly) | 37.76M |
| EPS Diluted (Quarterly) | -0.71 |
| Earnings Yield | -43.96% |
| Normalized Earnings Yield | -12.46 |